Head-to-head for women
Pallas Health vs Vaylen
Pallas Health and Vaylen both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Luna Fit Score — our women's-health rubric.
Pallas Health
Ranked #16 for women · Grade B−
Luna Fit
Best for: Readers who want a general compounded GLP-1 program with unusually specific disclosure about who prescribes and who dispenses, and who can absorb a $597 charge four weeks after the $139 one — not readers looking for PCOS or perimenopause care, which Pallas does not offer.
Visit Pallas HealthVaylen
Higher scoreRanked #22 for women · Grade B+
Luna Fit
Best for: Women who want maximum optionality — injectable or oral, compounded or brand — from an accredited, all-50-states provider.
Visit VaylenThe verdict for women
Vaylen edges out Pallas Health on the Luna Fit Score, 87 to 82 (B+ vs B−). Women who want maximum optionality — injectable or oral, compounded or brand — from an accredited, all-50-states provider. The reasoning behind that number is in what we found reviewing Vaylen.
Pallas Health is still a genuine option — names its six dispensing pharmacies and two NPI-verified physicians — disclosure few rows here offer — and then sells the whole thing on a single 12-week prepay whose advertised “$199/mo average” is that prepay divided by three, with no monthly rung to pick instead. Weigh the six women's-health factors below against your own priorities; the Pallas Health scorecard goes through each of them, and if neither of these two is the one, the full field we rank against Pallas Health widens the field.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | Pallas Health | Vaylen |
|---|---|---|
| Luna Fit Score | 82/100 · B− | 87/100 · B+ |
| Overall rank | #16 | #22 |
| Semaglutide | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, which is its only cadence; $139 covers the first 4 weeks, after which the next charge is $597 in one payment | $179/mo |
| Tirzepatide | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, which is its only cadence; $179 covers the first 4 weeks, after which the next charge is $897 in one payment | $239/mo |
| Coverage | All 50 states and Washington D.C. — asynchronous in 43; Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C. require one video visit | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Luna Fit
Pallas Health
Ranked #16 · Grade B−
What we like
- Names all six dispensing pharmacies in public — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A and 503B distinction explained, where almost everything else in this category names none
- Names two prescribing physicians with their NPI numbers and links out to the NPPES registry so you can check them yourself: Dr. Ana Lisa Carr, MD (family medicine, NPI-verified, licensed in 15 states) and Dr. Kelly Tenbrink, MD (emergency medicine, NPI-verified, Tennessee and Florida). Pallas additionally claims obesity and addiction medicine board certifications for Dr. Carr, which NPPES does not carry either way
- The advertised price is the checkout price — the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same four figures, and no different number appears at payment
The caveats
- There is no month-to-month rung. The funnel renders no cadence selector at all: semaglutide is $139 for the first four weeks and then $597 billed every 12 weeks, so the second charge is $597 in one payment four weeks after the first — tirzepatide, $179 then $897 — and the advertised “$199/mo average” is that 12-week prepay divided by three rather than a price anyone is billed
- Twelve weeks is not three months. On Pallas's own published renewal terms the charge recurs every 84 days — 4.35 times a year, not four — so semaglutide's first year is $139 + 4×$597 = $2,527, or $210.58/mo, and the steady state is $2,596 a year, about $216/mo, against $199 advertised. Tirzepatide runs $3,767 in year one ($313.92/mo) and about $3,900 a year after (~$325/mo) against $299. The advertised average understates the ongoing rate by roughly 8.7%
- No women's-health program of any kind. Pallas's own women's-health category exists only as “coming soon”; there is no PCOS track, no perimenopause track and no cycle-aware protocol, and neither named physician is an OB-GYN or a women's-health specialist. What is on offer here is a general compounded GLP-1 program, and it should be read as one
Luna Fit
Vaylen
Ranked #22 · Grade B+
What we like
- Offers an oral/sublingual route as well as injections — real choice for the needle-averse
- FDA-approved brand access plus compounded on both molecules
- LegitScript-accredited and available in all 50 states
The caveats
- Mid-tier pricing rather than the cheapest tiers
- Broad program rather than a dedicated PCOS/hormone clinic
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. Pricing, states and verification reflect each provider's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Neither Pallas Health nor Vaylen is only worth comparing with the other. Pallas Health is also written up against CoreAge Rx, 11 points apart on the Luna Fit Score — see Pallas Health against CoreAge Rx, factor by factor. Vaylen is also written up against Effecty, another exact tie — see the Vaylen–Effecty head-to-head.
- Pallas Health vs CoreAge Rx
- Pallas Health vs Enhance MD
- Pallas Health vs yourEra
- Vaylen vs Sesame Care
- Vaylen vs HealthRX
- Vaylen vs MadeMed
Or browse the full comparison hub.